



Sep 04, 2020

## ELISA for quantification of Vascular endothelial growth factor A (VEGFA) in cell culture supernatant, human serum or plasma

DOI

[dx.doi.org/10.17504/protocols.io.bkttkwnn](https://dx.doi.org/10.17504/protocols.io.bkttkwnn)

Angel A Justiz-Vaillant<sup>1</sup>, Belkis Ferrer-Cosme<sup>2</sup>

<sup>1</sup>University of the West Indies St. Augustine;

<sup>2</sup>"Saturnino Lora Torres" Provincial Teaching Clinical Surgical Hospital. Cuba

University of the West In...

angel.vaillant@sta.uwi.e...



Angel A Justiz-Vaillant

University of the West Indies St. Augustine

OPEN  ACCESS



DOI: [dx.doi.org/10.17504/protocols.io.bkttkwnn](https://dx.doi.org/10.17504/protocols.io.bkttkwnn)

**Protocol Citation:** Angel A Justiz-Vaillant, Belkis Ferrer-Cosme 2020. ELISA for quantification of Vascular endothelial growth factor A (VEGFA) in cell culture supernatant, human serum or plasma. **protocols.io**

<https://dx.doi.org/10.17504/protocols.io.bkttkwnn>

**License:** This is an open access protocol distributed under the terms of the **[Creative Commons Attribution License](#)**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Protocol status:** In development

We are still developing and optimizing this protocol

**Created:** September 04, 2020

**Last Modified:** September 04, 2020

**Protocol Integer ID:** 41555



## Disclaimer

### DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to **protocols.io** is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with **protocols.io**, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

- 1 An anti-vascular endothelial growth factor A (VEGFA) coating antibody is adsorbed onto the microwells by incubation overnight at 4°C with carbonate-bicarbonate buffer.
- 2 Add 50 µl of human serum. Human VEGFA present in the serum sample binds to antibodies adsorbed into the microwells.
- 3 The microplate is blocked with 3% non-fat milk-PBS buffer and later wash to remove unbound proteins.
- 4 Fifty (50) µl of biotin-conjugated anti-vascular endothelial growth factor A antibody is added. The optimal dilution must be investigated.
- 5 The microplate is rewashed with PBS-Tween 20 buffer, pH 7.4.
- 6 One hundred µl of streptavidin-HRP conjugate is added and it binds to the biotin-conjugated anti-human VEGFA antibody.
- 7 The plate is washed following incubation to remove the unbound Streptavidin-HRP conjugate.
- 8 Add 100 µl of 3,3',5,5'- tetramethylbenzidine (TMB; Sigma-Aldrich) into each well.
- 9 Incubate the microwells in the dark for 15 min.
- 10 A colored product is formed in proportion to the quantity of VEGFA present in the sample or standard.
- 11 The reaction is terminated by addition of 100 µl 3M H<sub>2</sub>SO<sub>4</sub> and the absorbance is measured at 450 nm.
- 12 A standard curve is made from 7 human VEGFA standard dilutions and the human VEGFA sample concentration is determined.



- 13 For better results place the microplate on a microplate shaker in every incubation.